|
|
||||||||
1From the Kallam Anji Reddy Molecular Genetics Laboratory, Brien Holden Eye Research Centre, Hyderabad Eye Research Foundation, Hyderabad, India; the 2Jasti V. Ramanamma Childrens Eye Care Centre, Hyderabad, India; the 3Centre for Sight Enhancement, Vision Rehabilitation Centres, L.V. Prasad Eye Institute, Hyderabad, India; and the 4Centre for DNA Fingerprinting and Diagnostics, Hyderabad, India.
PURPOSE. To establish the genotypephenotype correlations of various CYP1B1 (human cytochrome P450) mutations in patients in India with primary congenital glaucoma (PCG).
METHODS. The study cohort comprised 146 patients with PCG from 138 pedigrees. Patients were analyzed for six distinct CYP1B1 mutations by sequencing and polymerase chain reactionrestriction fragment length polymorphism (PCR-RFLP) methods. A severity index for grading various PCG phenotypes was constructed based on clinical parameters.
RESULTS. Six mutations were identified in 45 patients analyzed and genotypephenotype correlations were established for 43 of them. The percentages of severe phenotypes associated with various mutations in at least one eye were: frameshift, 100%; G61E, 66.7%; P193L, 62.5%; E229K, 80%; R368H, 72%; R390C, 83.3%. The frameshift mutation resulted in blindness. Based on the severity index, the disease severity was graded from normal to severe and the prognosis from good to very poor (blind). De novo mutation was identified in one family.
CONCLUSIONS. This is the first study to attempt to devise a severity index for grading various PCG phenotypes and to use genotype as an indicator to predict the prognoses of the disorder. This index may help guide therapy and counseling of the afflicted family regarding the progression of the disorder. All patients with severe phenotypes showed poor prognoses (r = 0.976; P < 0.0001). The data derived from this study could be used as an added clinical tool in disease management. Integrated management of PCG that makes use of a genetic approach could yield better results than medical, surgical, and rehabilitation interventions alone.
This article has been cited by other articles:
![]() |
F. Chitsazian, B. K. Tusi, E. Elahi, H. A. Saroei, M. H. Sanati, S. Yazdani, M. Pakravan, N. Nilforooshan, Y. Eslami, M. A. Z. Mehrjerdi, et al. CYP1B1 Mutation Profile of Iranian Primary Congenital Glaucoma Patients and Associated Haplotypes J. Mol. Diagn., July 1, 2007; 9(3): 382 - 393. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. S. Achary, A. B. M. Reddy, S. Chakrabarti, S. G. Panicker, A. K. Mandal, N. Ahmed, D. Balasubramanian, S. E. Hasnain, and H. A. Nagarajaram Disease-Causing Mutations in Proteins: Structural Analysis of the CYP1b1 Mutations Causing Primary Congenital Glaucoma in Humans Biophys. J., December 15, 2006; 91(12): 4329 - 4339. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Bidinost, N. Hernandez, D. P. Edward, A. Al-Rajhi, R. A. Lewis, J. R. Lupski, D. W. Stockton, and B. A. Bejjani Of mice and men: tyrosinase modification of congenital glaucoma in mice but not in humans. Invest. Ophthalmol. Vis. Sci., April 1, 2006; 47(4): 1486 - 1490. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Chakrabarti, K. Kaur, I. Kaur, A. K. Mandal, R. S. Parikh, R. Thomas, and P. P. Majumder Globally, CYP1B1 Mutations in Primary Congenital Glaucoma Are Strongly Structured by Geographic and Haplotype Backgrounds Invest. Ophthalmol. Vis. Sci., January 1, 2006; 47(1): 43 - 47. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |